Eli Lilly and Company

Indiana University

Assembly Biosciences, Inc.

William Wilson Turner, Jr

Lee Daniel Arnold

Hans Maag

Jeffrey S Nissen

Manuel Debono

Adam Zlotnick

Frederick J Burkhardt

Stephen A Hitchcock

Mark G Bures

Leping Li

Simon Nicolas Haydar

Samson Francis

Stacy Kay Henle

Timothy Alan Shepherd

Louis Nickolaus Jungheim

Peter S Borromeo

Jeffrey Daniel Cohen

Daniel Ray Mayhugh

George Stuart Gregory

Lichun Li

Jennifer Rebecca Allen

James Andrew Jamison

Bin Liu

Lynne Bannen

Roopa Rai

The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.

Cyclic sulfamide compounds and methods of using same

The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound of formula: 

Hepatitis B core protein modulators

The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

Hepatitis B core protein allosteric modulators

Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.

Hepatitis B viral assembly effectors

Novel virus assembly effector compounds having a therapeutic effect against Hepatitis B viral infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed are pharmaceutical compositions including the disclosed compounds, methods of treatment of HBV infection, and a process to synthesize the disclosed compounds.

Provided are compounds of the formula (1): wherein R' is hydrogen, methyl or NHC(O)CH&#x2014;;

Cyclic peptide antifungal agents and process for preparation thereof

The present invention relates to compounds of Formula I: Formula I which are agonists of the M-1 muscarinic receptor.

Muscarinic agonists

A method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal ornithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic peptide ring structure. The process allows one to incorporate features such as water-solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of members within the ring. The invention further provides novel Echinocandin type compounds and their use as antifungal or anti-parasitic agents.

Ring modified cyclic peptide analogs

Provided are compounds of the formula (1):wherein R' is hydrogen, methyl or NHC(O)CH&#x2014;;

A method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal omithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic peptide ring structure. The process allows one to incorporate features such as water-solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of members within the ring. The invention further provides novel Echinocandin type compounds and their use as antifungal or anti-parasitic agents.

Growing community of inventors

Bloomington, IN, United States of America

William Wilson Turner, Jr